Payment overview · 2025
General Payments
$573.64
36 reported records · 12 companies
Healthcare provider profile · identity verified
Peter Sidarous, MD
Allopathic & Osteopathic Physicians|Family Medicine · LITTLE ROCK, AR · NPI 1881072544
Verified facts
What the public records show
CMS Open Payments records show Peter Sidarous, MD received $573.64 in general payments during 2025 across 36 reported records.
Sumitomo Pharma America, Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $161.67 | 28.2% | 15 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $118.42 | 20.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.56 | 8.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.44 | 7.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.67 | 6.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.62 | 6.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.53 | 5.5% | 2 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $26.28 | 4.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $25.03 | 4.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.75 | 3.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.73 | 3.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.94 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $573.64 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $161.67 | 15 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $118.42 | 5 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $53.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.56 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.56 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.53 | 2 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 148 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
283 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
148 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Jardiance | Empagliflozin | 283 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 190 | 44 |
| Omeprazole | Omeprazole | 170 | 44 |
| Mounjaro | Tirzepatide | 148 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 126 | 35 |
| Meloxicam | Meloxicam | 125 | 36 |
| Metformin Hcl | Metformin Hcl | 106 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 91 | 19 |
| Glipizide Er | Glipizide | 82 | 17 |
| Gabapentin | Gabapentin | 79 | 23 |
| Linzess | Linaclotide | 76 | 19 |
| Simvastatin | Simvastatin | 67 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 12 |
| Gemtesa | Vibegron | 60 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 11 |
| Allopurinol | Allopurinol | 54 | suppressed |
| Furosemide | Furosemide | 53 | 11 |
| Losartan Potassium | Losartan Potassium | 53 | 15 |
| Celecoxib | Celecoxib | 51 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Ibuprofen | Ibuprofen | 45 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 30 |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Lisinopril | Lisinopril | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 14 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 22 | 15 |
| Baclofen | Baclofen | 22 | 12 |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 11 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | 12 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $573.64 · 36 records | Sumitomo Pharma America, Inc. | CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EBGLYSS, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, MOUNJARO, NUZYRA, ONZETRA XSAIL, OTEZLA, Ozempic, REPATHA, Rybelsus, XHANCE, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error